

## **August 2011 DUR BOARD MEETING MINUTES**

**Date:** August 24, 2011

**Members Present:** Wilkinson, Brown, Harrison, Crichton, Bradley, Burton, Fitzgerald, Maxwell, and Cobb (phone)

**Others Present:** Amy Holodnick, Dan Peterson, Bobbi Renner, Dave Campana (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

**Public Comment Period:** No one offered public comment at this time.

The July DUR Board PDL meeting minutes were reviewed and approved.

### **Department Update:**

Amy Holodnick, Medicaid Program Officer, gave the following update. There will be some upcoming pharmacy rule changes with the suggested addition of WAC to the State's outpatient prescription pharmacy payment methodology. In addition the State is proposing an increased dispensing fee for Preferred Brand products and Generic products. There will be a public hearing in October regarding the proposed rule change.

Amy then introduced the new DPHHS Pharmacist, Dave Campana, to the Board and public.

### **PDL Review:**

The Board made the following recommendations to the Department:

The Department proposed no changes to **GROUP 1** as all available chemical entities are preferred:

- **MACROLIDES**
- **IMMUNOSUPPRESSANTS**

The Board agreed with the Department's proposal

The Department proposed no changes to the Formulary Committee's previous clinical recommendations.

(The following classes were not reviewed because no **NEW** information was submitted)

- HERPETIC ANTIVIRALS- Class Effect
- 2<sup>nd</sup> GENERATION CEPHALOSPORINS-Class Effect
- 3<sup>rd</sup> GENERATION CEPHALOSPORINS- Class Effect.
- 2<sup>nd</sup> GENERATION QUINOLONES-Must have ciprofloxacin; all others have a class effect.
- 3<sup>rd</sup> GENERATION QUINOLONES-Moxifloxacin (Avelox) and levofloxacin are therapeutic alternatives; Gemifloxacin (Factive) is do not add.
- BENZOYL PEROXIDE/CLINDAMYCIN- Class Effect
- TOPICAL RETINOIDS-Must have adapalene; may add others. This class is grandfathered.
- ONCHOMYCOSIS ANTIFUNGALS-Must have terbinafine; may add itraconazole and griseofulvin
- TOPICAL ANTIBIOTICS-Must have a mupirocin product; may add retapamulin (Altabax).
- LEUKOTRINE MODIFIERS-Must have montelukast (Singulair); may add zafirlukast.
- NASAL CORTICOSTEROIDS- Class Effect
- SABA INHALERS & NEBS-The Board discussed the previous recommendation including levalbuterol (Xopenex) as a must add. The final decision was made that the agents in this group are Class Effect. The Board wants to grandfather patients currently on a specific medication.
- NASAL ANTIHISTAMINE- Class Effect

These were the final recommendations from the Board to the Department.

The Department reviewed the following classes as **NEW** information is known to exist:

- ANTIEMETICS (name changed from 5-HT3 Receptor Antagonists)- Ondansetron film (Zuplenz) and metoclopramide oral disintegrating tablets (Metozolv) were reviewed. The decision was class effect for the 5-HT3 agents, must have one; may add a metoclopramide.
- COPD AGENTS (name changed from Anticholinergics)- Roflumilast (Daliresp) was reviewed. Prior authorization criteria will continue as currently written for this agent. The PDL recommendation was must have ipratropium in some form; may add tiotropium (Spiriva); may have roflumilast (Daliresp).
- LABA COMBOS-Mometasone/formoterol inhaler (Dulera) was reviewed. Class effect, no grandfathering.
- LABA INHALERS & NEBS-Indacaterol inhalation powder (Arcapta) was reviewed. Class effect; must have one inhaler. No grandfathering.
- TOPICAL IMMUNOMODULATORS-Full class review. Prior authorization criteria in effect for this class. PDL recommendation: Class effect; must have one.
- ANTIHIISTAMINES-MIN SEDATING-Full class review. Previous prior authorization criteria will be removed. Class effect; must have one single ingredient agent.
- PAH AGENTS-Full class review. The decision was must have 1 ERA agent and 1 PDE-5. Patients on these medications will be grandfathered. The Board also requested criteria requiring a specialist consult prior to authorization of these agents.
- PANCREATIC ENZYMES-Full class review. Class effect with patients being grandfathered on current treatment.
- IMMUNOMODULATORS-Adalimumab (Humira) packaging update was reviewed. The Board held discussion on the Kineret (anakinra) decision from 2009 based on ADE and safety profile. The decision was to continue with class effect; do not add anakinra (Kineret).

The next meeting will be September 28, 2011 at the Great Northern, but in the Empire room.

The fall general DUR Board meeting is tentatively scheduled for October 19, 2011 at the Mountain Pacific Quality Health building.

The meeting was adjourned at 4:00.